ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Carboplatin is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it given beside what the study tests. Nov 2, 2026, 3:40 AM UTC
  • The role rule says the same.
  • So Carboplatin's page lists this study under “Given beside what is tested”.
7 links1 made here, not in the record10 judgments2 judges (the rules as one: Rule based)7 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05256225Testing the Addition ofHerceptin Hylecta or Phesgoto the Usual Chemotherapyfor HER2 PositiveEndometrial SerousCarcinoma or CarcinosarcomaNational Cancer Institute (NCIPhase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 25 · ClinicalTrials.gov record · Version of 2026-09-25Sep 28 · ClinicalTrials.gov record · Version of 2026-09-28Sep 29 · ClinicalTrials.gov record · Version of 2026-09-29Oct 1 · ClinicalTrials.gov record · Version of 2026-10-01Oct 2 · ClinicalTrials.gov record · Version of 2026-10-02Nov 12 · ClinicalTrials.gov record · Version of 2026-11-12Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSEndometrial NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionNeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPertuzumab/Trastuzumab/Hyal…Entry “Hyaluronidase-zzxf/Pertuzumab/…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT010168Entry “Trastuzumab/Hyaluronidase-oysk…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPertuzumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
7 versions of the record seen on ClinicalTrials.gov, Sep 25–Nov 18 · changes seen, not judgments
Nov 2CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 2Pertuzumab/Trastuzumab/Hyaluronidase-zzxfClaude Opus 5.5TestedCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2INT010168Claude Opus 5.5TestedCurrent
Nov 2Pertuzumabmade hereClaude Opus 5.5TestedCurrent
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18Pertuzumab/Trastuzumab/Hyaluronidase-zzxfRule based · role ruleTestedAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18INT010168Rule based · role ruleTestedAgrees
As of nowEndometrial NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.